145 related articles for article (PubMed ID: 10914711)
1. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
[TBL] [Abstract][Full Text] [Related]
2. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
[TBL] [Abstract][Full Text] [Related]
3. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
4. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
[TBL] [Abstract][Full Text] [Related]
7. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
Khayat D; Rixe O; Brunet R; Goupil A; Bugat R; Harousseau JL; Ifrah N; Puozzo C
Cancer Chemother Pharmacol; 2004 Sep; 54(3):193-205. PubMed ID: 15160284
[TBL] [Abstract][Full Text] [Related]
9. Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics.
Puozzo C; Gridelli C
Clin Lung Cancer; 2004 Jan; 5(4):237-42. PubMed ID: 14967076
[TBL] [Abstract][Full Text] [Related]
10. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
Bourgeois H; Vermorken J; Dark G; Jones A; Fumoleau P; Stupp R; Tourani J; Brain E; Nguyen L; Lefresne F; Puozzo C
Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone as a probe for vinorelbine clearance.
Puisset F; Dalenc F; Chatelut E; Cresteil T; Lochon I; Tisnes P; Roché H
Br J Clin Pharmacol; 2005 Jul; 60(1):45-53. PubMed ID: 15963093
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
15. A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
Anticancer Drugs; 2002 Jun; 13(5):473-80. PubMed ID: 12045458
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
18. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
Pieńkowski T; Jagiello-Gruszfeld A
Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
20. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
